http://www.infecto.edu.uy/terapeutica/atbfa/quino/quinolonas.

htm
O´Donnell J.A., Gelone S.P. Fluiroquinolones. Inf Dis Clin NA. 2000; 14:489-513
- Suh B., Lorber B. Quinolonas. Clin Med NA. Tratamiento antimicrobiano. Parte II. Ed.
Interamericana. Traducido al espaol. 1995;4:845-868.
- Hendershot E.F. Fluiroquinolones. Inf Dis Clin NA. 1995; 9(3):715-730.
- Sdaba Daz de Rada B., Escolar Jurado M., Azanza Perea J.R., Garca Quetglas E.
Quinolonas Medicina 1998;7(72): 3344-3353.
- Walker R.C. The Fluiroquinolones. Mayo Clin Proc. 1999;74:1030-1037.
- Heffelfinger J.D., Dowell S.F., Jorgensen J.H., et al. Management of CommunityAcquired Pneumonia in the Era of Pneumococcal Resistance. Arch Intern Med.
2000;160:1399-1408.
Dra. Mariela Vacarezza
https://es.wikipedia.org/wiki/8-hidroxiquinole%C3%ADna
Nmero CAS
-Hydroxyquinoline Safety Data. Oxford University. (enlace roto disponible en Internet
Archive; vase el historial y la ltima versin).
-8-Hydroxyquinoline. PAN Pesticides Database.
-Collin, G.; Hke, H. (2005), Quinoline and Isoquinoline, Ullmann's Encyclopedia of
Industrial Chemistry, Weinheim: Wiley-VCH, doi:10.1002/14356007.a22_465
-Albert, A.; Phillips, J. N. (1956). "264. Ionization Constants of Heterocyclic Substances.
Part II. Hydroxy-Derivatives of Nitrogenous Six-Membered Ring-Compounds". Journal of
the Chemical Society (Resumed) 1956: 12941304. doi:10.1039/JR9560001294.
-Bardez, E.; Devol, I.; Larrey, B.; Valeur, B. (1997). "Excited-State Processes in 8Hydroxyquinoline: Photoinduced Tautomerization and Solvation Effects". The Journal of
Physical Chemistry B 101 (39): 77867793. doi:10.1021/jp971293u.
-Phillips, J. P. (1956). The Reactions of 8-Quinolinol. Chemical Reviews 56 (2): 271
297. doi:10.1021/cr50008a003.
-8-Hydroxyquinoline. Sigma-Aldrich. Consultado el 23 de mayo de 2012.
-Shen, A. Y.; Wu, S. N.; Chiu, C. T. (1999). Synthesis and Cytotoxicity Evaluation of
some 8-Hydroxyquinoline Derivatives. Journal of Pharmacy and Pharmacology 51 (5):
543548. doi:10.1211/0022357991772826. PMID 10411213.
-Katakura, R.; Koide, Y. (2006). Configuration-Specific Synthesis of the Facial and
Meridional Isomers of Tris(8-hydroxyquinolinate)aluminum (Alq3). Inorganic Chemistry
45 (15): 57305732. doi:10.1021/ic060594s.
Montes, V. A.; Pohl, R.; Shinar, J.; Anzenbacher, P. Jr. (2006). Effective Manipulation of
the Electronic Effects and Its Influence on the Emission of 5-Substituted Tris(8quinolinolate) Aluminum(III) Complexes. Chemistry - A European Journal 12 (17):
45234535

https://es.wikipedia.org/wiki/Quinolona
-Bergan T.; Bayer (1988). "Pharmacokinetics of fluorinated quinolones". Academic
Press: 119154.
Volver arriba Orden Gutirrez, Jos Antonio and Fuente Lpez, Ricardo de la.
Repercusiones en la salud pblica de la resistencia a quinolonas en bacterias de origen
animal (en espaol). Rev. Esp. Salud Pblica 2001, vol.75, n.4 [cited 2009-12-30]
-Takei, M.; Fukuda, H.; Kishii, R.; Hosaka, M. Antimicrob. Agents Chemother. 2001, 45,
3544
-Heddle, J.; Maxwell, A. Antimicrob. Agents Chemother. 2002, 46, 1805.

-Llorente, B.; Leclerc, F.; Cedergren, R. Bioorg. Med. Chem. 1996, 4, 61.
-Lomaestro, B. M.; Bailie, G. R. Drug Saf. 1995, 12, 314.
-Polk, R. E. Am. J. Med. 1989, 87, 76S.
.Fresta, M.; Guccione, S.; Beccari, A. R.; Furneri, P. M.; Puglisi, G. Bioorg. Med. Chem.
2002, 10, 3871.
-Fresta, M.; Spadaro, A.; Cerniglia, G.; Ropero, I. M.; Puglisi, G.; Furneri, P. M. Antimicrob.
Agents Chemother. 1995, 39, 1372.
-Lomaestro, B. M.; Bailie, G. R. Drug Saf. 1995, 12, 314.
-Polk, R. E. Am. J. Med. 1989, 87, 76S.
-Mitscher, L. Chem. Rev. 2005, 105, 559-592. |http://pubs.acs.org/journal/chreay%7C
-Maury M. Breecher, PhD, MPH (17 de octubre de 2003). IDSA: Achilles Tendon Rupture
after use of antibiotics. Doctor's Guide
http://www.elsevier.es/es-revista-enfermedades-infecciosas-microbiologia-clinica-28articulo-quinolonas-13046545
1.Peterson LR. Quinolone molecular structure-activity relationships: What we have
learned about improving antimicrobial activity. Clin Infect Dis 2001;33(Suppl 3):180-6.
2.Domagala JM. Structure-activity and structure-side effect relationships for the
quinolone antibacterials. J Antimicrob Chemother 1994;33:685-706.
Medline
3.Naber KB, Adam D. Classification of fluorquinolones. Int J Antimicrob Agents
1998;10:255-7.
Medline
4.Owens RC Jr, Ambrose PG. Clinical use of the fluoroquinolones. Med Clin North Am
2000;84:1447-69.
Medline
5.Bergogne-Berezin E. Clinical role of protein binding of quinolones. Clin Pharmacokinet
2002;41:741-50.
Medline
6.Walker RC. The fluoroquinolones. Mayo Clin Proc 1999;74:1030-7.
Medline
7.Amsden GW, Ballow CH, Bertino JS Jr. Pharmacokinetics and pharmacodynamics of
anti-infective agents. En: Mandell GL, Bennett JE, Dolin R, editors. Principles and
practice of infectious diseases. 5th ed. New York: Churchill Livingstone, 2000; p. 25361.
8.Lister PD, Sanders CC. Pharmakodinamics of levofloxacin and ciprofloxacin against
Streptococcus pneumoniae. J Antimicrob Chemother 1999;43:79-86.
Medline
9.Als JI, Oteo J, Aracil B, Gmez-Garcs JL. Comparative in vitro study of the activity of
moxifloxacin and other antibiotics against 150 strains of penicillin non-susceptible
Streptococcus pneumoniae and against 110 strains of ampicillin-resistant Haemophilus
influenzae isolated in 1999-2000 in Spain. J Antimicrob Chemother 2001;48:145-8.
Medline
10.Hooper DC. Mechanism of action of antimicrobials: Focus on fluoroquinolones. Clin
Infect Dis 2001;32(Suppl 1):9-15. Medline

https://en.wikipedia.org/wiki/Clopidol

-Raimund Miller, Claudio Abaecherli, Adel Said, Barry Jackson "Ketenes" in Ullmann's
Encyclopedia of Industrial Chemistry, 2001, Wiley-VCH, Weinheim. doi:
10.1002/14356007.a15_063
-"Clopidol". Pocket Guide to Chemical Hazards. NIOSH.

http://escuela.med.puc.cl/publ/boletin/osteoporosis/UtilidadMarcadores.html
1. Delmas PD. The role of markers of bone turnover in the assessment of fracture risk in
post menopausal women. Osteoporosis Int 1998; 8 (Suppl 1): S32-36.
2. Garnero P, Shih WJ, Gineyts E, Karpf DB, and Delmas PD. Comparison of new
biochemical markers of bone turnover in late postmenopausal osteoporotic women in
response to alendronate treatment. Clin Endocrinol Metab 1994; 79: 1693-700.
3. Calvo MS, Eyve DR, Gundberg CM. Molecular basis and clinical application of
biological markers of bone turnover. Endocr Rev, 1996; 17: 333-68.
4. Campusano C, Lpez JM, Gonzlez G y cols. Marcadores bioqumicos de
remodelamiento y densidad sea en la postmenopausia. Rev Med Chile 1993; 121:
1000-5.
5.Villaseca P, Arteaga E, Campusano C, y cols. Modificacin de la reabsorcin sea con
terapia hormonal de reemplazo en la postmenopausia. Rev Med Chile 1996; 124:143946.
6.Riis SBJ, Hansen AM, Jensen K, Overgaard K and Christiansen C. Low bone mass and
fast rate of bone loss at menopause-equal risk factors for future fracture. A 15 years
follow up study. Bone 1996; 19: 9-12.
7.Hassager C, Fabbri-Mabelli G and Christiansen C. The effect of the menopause and
hormone replacement therapy on serum carboxy terminal propeptide of type I collagen.
Osteoporosis Int 1993; 3: 50-2.
http://www.bioacademia.com.mx/miembros/asesoriabiomedica/bioquimicaclinica/0009.
html
-ROBINS SP. ACTA ORTHOP SCAND. 1995;66: 171-175.
-VESPER HW ET AL. ANAL BIOCHEM 2003; 318:204-211.
-CLINICAL LABORATORY STANDARDS INSTITUTE. APPLICATION OF BIOCHEMICAL
MARKERS OF BONE TURNOVER IN THE ASSESSMENT AND MONITORING OF BONE
DISEASES: APPROVED GUIDELINE. NCCLS DOCUMENT C48-A, WAYNE, PENNSYLVANIA.
2004.
VESPER HW ET AL. CLIN CHEM 2002; 48:220-235.
-ROBINS SP. CURR OPIN CLIN NUTR METAB CARE 2003; 6:65-71.
-VESPER HW ET AL. CLINICAL CHEMISTRY 2001; 47:2029-2031.
-NISHIZAWA Y ET AL. J BONE MINER RES 2001; 19:338-344.
-ROSEN HN ET AL. CALCIF TISSUE INT 2000; 66: 100-103.
-HANNON R ET AL. J BONE MINER RES 1998; 13: 1124-1133.
-DELMAS PD ET AL. OSTEOPOROS INT 2000; 11 :S2-S17.

-Reporte 123-31-9. Agencia Federal de Proteccin al Medio Ambiente de Estados Unidos

(EPA). En ingls. http://www.epa.gov/iris/subst/0508.htm
Criterios de Salud Ambiental 157 / Hidroquinona. Publicado en la base de datos de
seguridad de productos qumicos de organizaciones intergubernamentales del
Programa Internacional de Seguridad Qumica y Informacin (IPCS INCHEM). Texto en
ingls con resumen en francs y espaol

https://es.wikipedia.org/wiki/Hidroquinona
-Gua 101 "Salud y Seguridad". Programa Internacional de Seguridad Qumica (IPCS,
por sus siglas en ingls), Agencia Federal de Proteccin al Medio Ambiente de Estados
Unidos (EPA), Organizacin Internacional del Trabajo (OIT) y Organizacin Mundial de la
Salud (OMS). En ingls. http://www.inchem.org/documents/hsg/hsg/hsg101.htm
-Estudio sobre Toxicologa y Carcinognesis de la Hidroquinona (TR-366). Programa
Nacional de Toxicologa (NTP) de Estados Unidos. Extracto en ingls.
http://ntp.niehs.nih.gov/?objectid=0708C8DF-95C1-3EAD-8F4EF9AF16B25540
https://es.wikipedia.org/wiki/Hidroquinona_(farmacolog%C3%ADa)
1.

Pubchem. Hydroquinone (en ingls). Consultado el 9 de noviembre de 2012. Nombre

IUPAC.

2. A. Swinyard, Ewart; Madhu A. Pathak (1988). Goodman And Gilman's The Pharmacological
Basis Of Therapeutics (7 edicin). Mxico: The McGraw-Hill. p. 910. ISBN 950-06-0847-2.
3.

FDA (2006). Skin Bleaching Drug Products For Over-the-Counter Human Use (PDF) (en
ingls). Estados Unidos. Consultado el 9 de noviembre de 2012.

http://bvs.sld.cu/revistas/act/vol8_1_98/act08198.htm

Greenfield RA. Symposium on antimicrobial therapy VII: The fluorquinolones. J Okla

State Med Assoc 1993;86:166-74.
Rubinstein E, Adam D. International Symposium on new quinolones, Rev Infec Dis
1988;10 (Suppl I):
Lesher GY, Froelich DE, Gruet MD. 1-8-Naphtydine derivates: a new class of
chemotherapeutic agents. J Med Pharm Chem 1962;5:1063-8.
Barlow AM. Nalidixic acid in infections of urinary tract. Br Med J 1963;2:1208-1310.
New HC. New antibiotics; areas of appropriate use. J Infect Dis 1987;155:403-17.
Lambert HP, OGrady FW. Quinolones. En: Antibiotic and chemotherapy churchill
livingstone. 6 ed. Londres 1992:245-62.
Hooper DC, Wolfson JS. Fluorquinolone antimicrobial agents. N Engl J Med 1991;324-94.
New CH. Quinolonas: nuevos antimicrobianos con amplias posibilidades de uso. Clin
Med Norteam 1987;71:663-7.
Bakken JS. Norfloxacin: mechanism of action, safety and effectiveness. Infect Dis
1990;4:129-43.
Andriale VT. Fleroxacn: the newly introduced once- dialy quinolone. Int J Antimicrob
Agents 1994;4 (Suppl 2):S1-S6.
Smith JT, Lewin S. Qumica y mecanismos de accin de los antibacterianos quinolonas.
En: las quinolonas. Andriole VI de. San Diego: Academic, 1989:25-89.
Rubinstein E, Carbon S. The fluorquinolones- reappraisal. Int J Antimicrob Agents
1992;4:147-52.
Nightingale CH. Implications of fleroxacins pharmacokinetic profile. Int J Antimicrob
Agents 1994;4(Suppl 2):S7-S13.
Hooper DC, Wolfson JS. Mechanismo of action and resistance to ciprofloxacin. Am J Med
1987;82(Suppl 4 A):12-20.

Mouton Y, Leroy O. Ofloxacin. Int J Antimicrob Agents 1991;1: 57-74.

Hooper DC, Wolfson JS. Mode of action of the quinolone antimicrobial agents; review of
recent information. Rev Infect Dis 1989;2(Suppl 5):S902-S908.
Goldstein FW, Acar JF. Epidemiology of quinolone resistance: Europe and North and
South America. Drug 1995;49(Suppl 2): 36-42.